Navigation Links
Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Date:12/20/2007

CLEVELAND, OH and VANCOUVER, Dec. 20 /PRNewswire-FirstCall/ - Athersys, Inc. (Nasdaq: ATHX) and Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), announced today that Athersys has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the safety of MultiStem(R) in the treatment of acute myocardial infarction (AMI). The companies believe that this represents the first clinical study of a scalable, allogeneic cell product injected directly into and around the zone of myocardial injury from an intra-coronary approach. This approach is designed to provide the clinician with a readily usable, "off-the-shelf" cell therapy that combines the benefits of efficient, localized delivery and enhanced cell retention in the area of greatest need.

Angiotech and Athersys entered into an agreement in May 2006 to co-develop and commercialize MultiStem(R), Athersys' non-embryonic stem cell platform technology, for use in the indications of AMI and peripheral vascular disease. Upon completion of the Phase I trial, Angiotech will assume lead responsibility for further clinical development. Angiotech also owns marketing and commercial rights with respect to this product candidate.

"Stem cell therapy offers the promise of restoring the functionality of damaged heart tissue, helping patients return to a more normal lifestyle following serious heart attacks. We believe that the MultiStem(R) technology has demonstrated significant promise in the preclinical setting and has the potential to be an effective "off-the-shelf" cell therapy product for the interventional cardiologist," commented Dr. Jeff Walker, Senior VP, Research and Development for Angiotech.

"Building on the suc
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... ... to provide online tutorial suite, Quick Reference Cards, and other training and outreach programs. ... Seattle, WA (PRWEB) April 13, ... has partnered with OpenHelixTM to provide comprehensive training and outreach programs for its ...
... Researchers at Uppsala University have developed a new method ... Hopes are strong that the method represents an important ... new diagnostic tests. The new method, which ... should enable studies of the effects of genetic variation ...
... ... Deliver Results Faster with New User Interface and Improved Support for Complex Experiments. ... (PRWEB) April 12, ... life science research, today announced Genedata Screener® 8. Developed over the past year to ...
Cached Biology Technology:RCSB PDB Teams with OpenHelix to Announce Free Tutorial and Training Materials 2RCSB PDB Teams with OpenHelix to Announce Free Tutorial and Training Materials 3Mutations directly identifiable in active genes 2Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference 2Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference 3Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference 4
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... Calif. Each year, dengue fever infects as many as ... 30,000 deaths worldwide. Both diseases are spread by infected ... to produce eggs. The blood feeding and the egg development ... virus. Now a team of entomologists at the University ...
... a jetliner act and feel one way when crammed together ... different mindset when the middle seat is empty and they ... that exists among the proteins involved in health and disease ... of Chemical & Engineering News (C&EN), ACS, weekly newsmagazine, focuses ...
... 2, 2010) SAGE has extended its suite of ... two titles: Therapeutic Advances in Drug Safety , ... Therapeutic Advances in Drug Safety covers novel ... drugs in different age and ethnic patient groups, drug ...
Cached Biology News:Discovery by UC Riverside entomologists could shrink dengue-spreading mosquito population 2